Uveitis in juvenile idiopathic arthritis: when to stop adalimumab?
- PMID: 39863351
- DOI: 10.1016/S0140-6736(24)02616-3
Uveitis in juvenile idiopathic arthritis: when to stop adalimumab?
Conflict of interest statement
DF has received consulting fees and research grants from Boehringer, Fresenius Kabi, Novartis, and Sobi Swedish Orphan Biovitrum; and received speaker honoraria from BionTech Pfizer, Novartis, and Sobi Swedish Orphan Biovitrum. AH declares no competing interests.
Comment on
-
Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.Lancet. 2025 Jan 25;405(10475):303-313. doi: 10.1016/S0140-6736(24)02468-1. Lancet. 2025. PMID: 39863370 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
